Sunesis Pharmaceuticals Reports First Quarter 2014 Financial Results And Recent Highlights
5/7/2014 8:57:12 AM
SOUTH SAN FRANCISCO, Calif., May 7, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the quarter ended March 31, 2014. Loss from operations for the three months ended March 31, 2014 was $9.0 million. As of March 31, 2014, cash, cash equivalents and marketable securities totaled $70.7 million. Sunesis also announced today that it has received U.S. Food and Drug Administration (FDA) acceptance for the use of Qinprezo™ as the trademark name for its vosaroxin product candidate. The company received a similar acceptance from the European Medicines Agency in 2013.
Help employers find you! Check out all the jobs and post your resume.